Stifel Financial Corp Lowers Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Stifel Financial Corp trimmed its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 7.0% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,694,153 shares of the biopharmaceutical company's stock after selling 127,911 shares during the period. Stifel Financial Corp owned 0.14% of Gilead Sciences worth $156,490,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Tower Research Capital LLC TRC lifted its holdings in shares of Gilead Sciences by 184.5% during the fourth quarter. Tower Research Capital LLC TRC now owns 109,283 shares of the biopharmaceutical company's stock valued at $10,094,000 after acquiring an additional 70,872 shares during the period. Transce3nd LLC acquired a new position in shares of Gilead Sciences during the 4th quarter worth about $99,000. MetLife Investment Management LLC grew its holdings in shares of Gilead Sciences by 1.9% in the 4th quarter. MetLife Investment Management LLC now owns 329,898 shares of the biopharmaceutical company's stock valued at $30,473,000 after buying an additional 6,109 shares during the period. Norinchukin Bank The increased its holdings in shares of Gilead Sciences by 9.2% in the fourth quarter. Norinchukin Bank The now owns 68,098 shares of the biopharmaceutical company's stock worth $6,290,000 after acquiring an additional 5,726 shares in the last quarter. Finally, Ossiam boosted its holdings in shares of Gilead Sciences by 3.2% in the fourth quarter. Ossiam now owns 31,975 shares of the biopharmaceutical company's stock valued at $2,954,000 after buying an additional 1,006 shares during the period. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Price Performance

NASDAQ GILD traded down $2.98 during mid-day trading on Friday, hitting $103.17. The stock had a trading volume of 14,207,585 shares, compared to its average volume of 7,556,747. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $119.96. The stock has a market capitalization of $128.46 billion, a price-to-earnings ratio of 278.84, a PEG ratio of 0.71 and a beta of 0.32. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. The firm's 50 day moving average is $109.26 and its 200 day moving average is $98.03.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.73 by $0.08. The company had revenue of $6.67 billion during the quarter, compared to analysts' expectations of $6.77 billion. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. During the same quarter last year, the firm earned ($1.32) earnings per share. Equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Friday, June 13th will be given a dividend of $0.79 per share. The ex-dividend date is Friday, June 13th. This represents a $3.16 annualized dividend and a dividend yield of 3.06%. Gilead Sciences's dividend payout ratio is currently 854.05%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 142,180 shares of the company's stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $97.22, for a total transaction of $13,822,739.60. Following the completion of the sale, the chief financial officer now directly owns 129,873 shares of the company's stock, valued at $12,626,253.06. This represents a 52.26 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold 302,785 shares of company stock worth $30,540,875 over the last three months. Insiders own 0.27% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have recently commented on GILD. Wells Fargo & Company increased their price objective on Gilead Sciences from $120.00 to $140.00 and gave the company an "overweight" rating in a report on Wednesday, March 5th. BMO Capital Markets increased their price target on shares of Gilead Sciences from $110.00 to $115.00 and gave the stock an "outperform" rating in a research report on Wednesday, February 12th. JPMorgan Chase & Co. boosted their target price on shares of Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a research note on Thursday, March 27th. Cantor Fitzgerald assumed coverage on shares of Gilead Sciences in a research note on Tuesday. They set an "overweight" rating and a $125.00 price target for the company. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Gilead Sciences in a research report on Friday. Nine research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and four have issued a strong buy rating to the company. According to MarketBeat.com, Gilead Sciences has a consensus rating of "Moderate Buy" and an average target price of $108.42.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.